Text Size
50 studies found for:    Blood Transfusion | Open Studies | NIH, U.S. Fed

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Conditions: Anemia, Aplastic;   Anemia, Hypoplastic;   Thrombocytopenia
Interventions: Drug: Eltrombopag (Promacta);   Drug: Eltrombopag
22 Recruiting Massive Iron Deposit Assessment
Conditions: Iron Overload;   Excessive Body Iron Burden
Interventions: Device: R2*-UTE;   Device: R2*-GRE;   Procedure: Liver biopsy
23 Recruiting Simplified Severe Sepsis Protocol in Zambia
Conditions: Sepsis;   Severe Sepsis
Intervention: Other: Simplified Severe Sepsis Protocol
24 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
25 Recruiting Screening for Subjects to Participate in Studies of Blood Disorders
Conditions: Bone Marrow Transplant;   Sickle Cell Disease
Intervention:
26 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath(Registered Trademark))
27 Recruiting Alemtuzumab (Campath(Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia
Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)
28 Recruiting Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Conditions: Anemia, Aplastic;   Anemia, Hypoplastic
Interventions: Drug: h-ATG (ATGAM(Registered Trademark));   Drug: Cyclosporine (Gengraf(Registered Trademark))
29 Recruiting Identification of Early Predictors of Fetomaternal Hemorrhage
Conditions: Fetomaternal Hemorrhage;   Neonatal Anemia
Intervention:
30 Recruiting Treatment of Hemochromatosis
Condition: Hemochromatosis
Intervention:
31 Recruiting Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis
Condition: Healthy
Intervention: Drug: Acetylcholine and Blood
32 Recruiting Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
Condition: Kidney Transplantation
Intervention: Procedure: Kidney transplantation
33 Recruiting Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
34 Recruiting Genetic Studies of Chronic Active Epstein-Barr Disease
Condition: Epstein-Barr Virus Infections
Intervention:
35 Recruiting Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Biological: filgrastim;   Drug: fludarabine phosphate;   Drug: cytarabine;   Procedure: ex vivo-expanded cord blood progenitor cell infusion
36 Recruiting Treating Patients With High-Grade Glioma With IA Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate
Conditions: Brain and Central Nervous System Tumors;   Thrombocytopenia
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide phosphate;   Drug: Etoposide;   Drug: Sodium thiosulfate
37 Not yet recruiting Control of Major Bleeding After Trauma Study
Conditions: Trauma;   Hemorrhagic Shock
Interventions: Biological: Type AB plasma;   Drug: Crystalloid fluid (standard of care for resuscitation)
38 Recruiting Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
Conditions: Arterial Thromboembolic Events;   Atrial Fibrillation
Interventions: Drug: Placebo;   Drug: Dalteparin
39 Recruiting Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation
Condition: Diabetes Mellitus, Type I
Interventions: Drug: Low Molecular Weight Sulfated Dextran (LMW-SD);   Drug: Heparin;   Drug: CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus);   Drug: Prograf® (Tacrolimus) OR Cyclosporine;   Drug: Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant;   Drug: Simulect® (Basiliximab) - at 2nd or 3rd transplant;   Drug: Klexane® (Enoxaparinsodium);   Drug: Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA);   Drug: Enbrel® (Etanercept)
40 Recruiting Aflibercept in Treating Patients With Myelodysplastic Syndromes
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Secondary Myelodysplastic Syndromes
Interventions: Biological: ziv-aflibercept;   Other: laboratory biomarker analysis;   Other: pharmacological study
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-50) Show next page of results
† Indicates status has not been verified in more than two years